Artificial Intelligence: A Way to Promote Innovation
DOI:
https://doi.org/10.69996/jsihs.2024001Keywords:
Artificial intelligence, Clinical studies Challenges, innovations, complications of diseases, cloud computingAbstract
The theme of artificial intelligence is how to use it to make computers useful in solving problems concerning health. We interpret the data obtained by diagnosing various diseases, such as various types of cancer, diabetes, etc. The largest scientific goal of information construction—the theory of processing intelligence. It is the science and engineering of manufacturing. Intelligent machines, especially an intelligent computer. This work presents artificial intelligence (A.I.). Study how to make computers that have some characteristics of the human mind. A.I. systems are now routinely used in the economy, Medicine, and the military. They also have broad data that can potentially solve many problems in clinical trials. This article provides an overview of A.I. and its innovations. It is one of the cutting-edge technologies shaping the future of pharmacy. Various advanced systems, such as mathematics, machining performance, cloud computing, and algorithm design, have accelerated the development of methods that can be used to analyze, interpret, and make predictions using these data sources. We can learn how to get machines to solve problems by observing others.There has been sporadic research growth in two main areas: genomics and digital Medicine. This article examines the introduction, definition, history, applications, and innovation in pharmacy.
References
[1] P.E.Agre, “Computational research on interaction and agency,” Artificial Intelligence, vol.72, pp.1-52, 1995.
[2] K.Nakajima, S.Matsuo and H.Wakabayashi, “Diagnostic performance of artificial neural network for detecting Ischemia in myocardial perfusion imaging,” Circulation Journal, vol.79, no.7, pp.1549-56, 2020.
[3] https://builtin.com/artificialintelligence/artificial-intelligence-healthcare; 08- 03-2007.
[4] P.E.Marik and N.L.Janower, “The impact of routine chest radiography on ICU management decisions: An observational study,” Am J Crit Care, vol.6, pp.95–98, 1997.
[5] Amit Shovon Ray, “Learning and innovation in the Indian pharmaceutical industry: the role of IPR and other policy interventions,” RECIIS – Elect. J. Commun. Inf. Innov. Health, vol.2, no.2, pp.71-77, 2010.
[6] P. Verwer and F.J.J. Leusen, "Computer Simulation to Predict Possible Crystal Polymorphs" in Reviews in Computational Chemistry, K.B. Lipkowitz and D.B. Boyd, Eds., Wiley-VCH:New York, vol. 12, pp.327-365, 1998.
[7] E.A.Gehan and N. A. Lemak, “Statistics in Medical Research: Developments in Clinical Trials,” New York:Plenum Medical Book, 1994.
[8] https://www.forbes.com/sites/cognitiveworld/2019/06/19/7-types-of artificial intelligence (“types of AI”)
[9] https://pdfs.semanticscholar.org/973a/c1c8452415fa 16dea80b694574ceed0d4364.pdf (“types ofES”)
[10] https://dataprot.net/statistics/ai-statistics/ ("key statistics of A.I.")
[11] https://en.wikibooks.org/wiki/The_Computer_Rev solution/Artificial_Intelligence/Expert_Systems (“benefits of Expert systems”)
[12] Hu Z, Ge Q, Jin L, Xiong M. Artificial intelligence forecasting of COVID-19 in China. arXiv preprint arXiv:2002.07112. 2020 Feb 17.
[13] J. Stebbing, A. Phelan, I. Griffin, C. Tucker, O. Oechsle et al., “COVID-19: combining antiviral and antiinflammatory treatments,” Lancet Infect Dis., vol.20, no.4, pp.400-402, 2020.
[14] Expert system team (2019) Expert system, what is machine learning? A definition. https://www.expertsystem.com/machine-learningdefinition
[15] A. Haleem, M. Javaid and R.Vaishya, “Effects of COVID 19 pandemic in daily life,” Curr Med Res Pract, vol.10, no.2, pp.78-79 2020.
[16] H.X. Bai, B. Hsieh, Z. Xiong, K. Halsey, J.W. Choi, et al., “Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest C.T.," Radiology, vol.296, no.2, pp.E46- E54,2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Sensors, IoT & Health Sciences (JSIHS,ISSN: 2584-2560)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Fringe Global Scientific Press publishes all the papers under a Creative Commons Attribution-Non-Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/) license. Authors have the liberty to replicate and distribute their work. Authors have the ability to use either the whole or a portion of their piece in compilations or other publications that include their own work. Please see the licensing terms for more information on reusing the work.
